Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) traded down 14.3% during trading on Wednesday . The company traded as low as C$0.06 and last traded at C$0.06. 523,322 shares changed hands during trading, an increase of 443% from the average session volume of 96,435 shares. The stock had previously closed at C$0.07.
Hemostemix Price Performance
The company’s 50-day simple moving average is C$0.07 and its two-hundred day simple moving average is C$0.06. The firm has a market capitalization of C$5.23 million, a P/E ratio of -3.00 and a beta of 0.15.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.
Read More
- Five stocks we like better than Hemostemix
- Low PE Growth Stocks: Unlocking Investment Opportunities
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- 3 Fintech Stocks With Good 2021 Prospects
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- What is a Stock Market Index and How Do You Use Them?
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
